Optimal design of a single recombinant adeno-associated virus derived from serotypes 1 and 2 to achieve more tightly regulated transgene expression from nonhuman primate muscle

Molecular Therapy

Volumn 9, Issue 3, 2004, Pages 410-418

  Chenuaud, Pierre ^a   Larcher, Thibaut ^a   Rabinowitz, Joseph E ^b   Provost, Nathalie ^a   Joussemet, Béatrice ^c   Bujard, Hermann ^d   Samulski, Richard J S ^b   Favre, David ^e   Moullier, Philippe ^f  

^a HÔTEL DIEU   (France)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITÉ DE NANTES   (France)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e GLADSTONE INSTITUTES   (United States)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; DOXYCYCLINE; ERYTHROPOIETIN; PARVOVIRUS VECTOR; TETRACYCLINE; TRANSACTIVATOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE CASSETTE; GENE EXPRESSION REGULATION; GENE INDUCTION; GENETIC TRANSCRIPTION; HEPATITIS VIRUS; IN VIVO STUDY; MALE; MOLECULAR CLONING; MOUSE; MUSCLE; NONHUMAN; PRIMATE; REPORTER GENE; SENSITIVITY ANALYSIS; SEROTYPE; TRANSGENE; VIRUS RECOMBINANT; VIRUS TYPING;

ADENO-ASSOCIATED VIRUS; MAMMALIA; MARMOTA MONAX; PRIMATES; WOODCHUCK HEPATITIS B VIRUS;

EID: 1642525149     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2003.12.015     Document Type: Article

References (40)

1. Muzyczka, N. (1992). Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr. Top. Microbiol. Immunol. 158: 97-129.
2. Snyder, R. O. (1999). Adeno-associated virus-mediated gene delivery. J. Gene Med. 1: 166-175.
3. Manna, C. S., et al. (2002). AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 19: 19.
4. Monahan, P. E., and Samulski, R. J. (2000). Adeno-associated virus vectors for gene therapy: More pros than cons? Mol. Med. Today 6: 433-440.
5. Gossen, M., and Bulard, H. (1992). Tight control of gene expression in mammalian cells by tetracyclin-responsive promoters. Proc. Natl. Acad. Sci. USA 89: 5547-5551.
6. Wang, Y., DeMayo, F. J., Tsai, S. Y., and O'Malley, B. W. (1996). Ligand-inducible and liver-specific target gene expression in transgenic mice. Nat. Biotechnol. 15: 239-243.
7. No, D., Yao, T. P., and Evans, R. M. (1996). Ecdysone-inducible gene expression in mammalian cells and transgenic mice. Proc. Natl. Acad. Sci. USA 93: 3346-3351.
8. Rivera, V. M., et al. (2002). A humanized system for pharmacologic control of gene expression. Nat. Med. 2: 1028-1032.
9. Bohl, D., Salvetti, A., Moullier, P., and Heard, J. M. (1998). Control of erythropoietin delivery by doxycyclin in mice after intramuscular injection of adeno-associated vector. Blood 92: 1512-1517.
10. Favre, D., et al. (2002). Lack of immune response against the tetracycline-dependent transactivator correlates with long-term doxycycline-regulated transgene expression in nonhuman primates after intramuscular injection of recombinant adeno-associated virus. J. Virol. 76: 11605-11611.
11. Hillen, W., and Berens, C. (1994). Mechanisms underlying expression of Tn10 encoded tetracycline resistance. Annu. Rev. Microbiol. 48: 345-369.
12. Gossen, M., et al. (1995). Transcriptional activation by tetracyclines in mammalian cells. Science 268: 1766-1769.
13. Urlinger, S., et al. (2000). Exploring the sequence space for tetracycline-dependent transcriptional activators: Novel mutations yield expanded range and sensitivity. Proc. Natl. Acad. Sci. USA 97: 7963-7968.
14. Flotte, T. R., et al. (1993). Expression of the cystic fibrosis transmembrane conductance regulator from a novel adeno-associated virus promoter. J. Biol. Chem. 268: 3781-3790.
15. Haberman, R. P., McCown, T. J., and Samulski, R. J. (2000). Novel transcriptional regulatory signals in the adeno-associated virus terminal repeat A/D junction element. J. Virol. 74: 8732-8739.
16. Loeb, J. E., Cordier, W. S., Harris, M. E., Weitzman, M. D., and Hope, T. J. (1999). Enhanced expression of transgenes from adeno-associated virus vectors with the woodchuck hepatitis virus posttranscriptional regulatory element: Implications for gene therapy. Hum. Gene Ther. 10: 2295-2305.
17. Zufferey, R., Donello, J., Trono, D., and Hope, T. (1999). Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J. Virol. 73: 2886-2892.
18. Samulski, R. J., Chang, L. S., and Shenk, T. (2002). Helper-free stocks of recombinant adeno-associated viruses: Normal integration does not require viral gene expression. J. Virol. 63: 3822-3828.
19. Niwa, H., Yamamura, K., and Miyazaki, J. (1989). Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108: 193-199.
20. Li, Z., and Paulin, D. (1991). High level desmin expression depends on a muscle-specific enhancer. J. Biol. Chem. 266: 6562-6570.
21. Grimm, D., Kern, A., Rittner, K., and Kleinschmidt, J. (1998). Novel tools for production and purification of recombinant adeno-associated virus vectors. Hum. Gene Ther. 9: 2745-2760.
22. Favre, D., et al. (2001). Immediate and long-term safety of recombinant adeno-associated virus injection into the nonhuman primate muscle. Mol. Ther. 4: 559-566.
23. Rabinowitz, J. E., et al. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76: 791-801.
24. Salvetti, A., et al. (1998). Factors influencing recombinant adeno-associated virus production. Hum. Gene Ther. 9: 695-706.
25. Xiao, W., et al. (1999). Gene therapy vectors based on adeno-associated virus type 1. J. Virol. 73: 3994-4003.
26. Arruda, V. R., et al. (2004). Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1. Blood 103: 85-92.
27. Fender, P., et al. (2002). Controlled transgene expression by E1S-E4-defective adenovirus vectors harbouring a "tEt-on" switch system. J. Gene Med. 4: 668-675.
28. Lindemann, D., Patriquin, E., Feng, S., and Mulligan, R. C. (1997). Versatile retrovirus vector systems for regulated gene expression in vitro and in vivo. Mol. Med. 3: 466-476.
29. Freundlieb, S., Schirra-Muller, C., and Bujard, H. (1999). A tetracycline controlled activation/repression system with increased potential for gene transfer into mammalian cells. J. Gene Med. 1: 4-12.
30. Smith-Arica, J. R., et al. (2000). Cell-type-specific and regulatable transgenesis in the adult brain: Adenovirus-encoded combined transcriptional targeting and inducible transgene expression. Mol. Ther. 2: 579-587.
31. Smith-Arica, J. R., et al. (2000). Switching on and off transgene expression within lactotrophic cells in the anterior pituitary gland in vivo. Endocrinology 142: 2521-2532.
32. Salucci, V., et al. (2002). Tight control of gene expression by a helper-dependent adenovirus vector carrying the rtTA2(s)-M2 tetracycline transactivator and repressor system. Gene Ther. 9: 1415-1421.
33. McGee Sanftner, L. H., et al. (2001). Recombinant AAV-mediated delivery of a tet-inducible reporter gene to the rat retina. Mol. Ther. 3: 688-696.
34. Rendahl, K. G., et al. (2002). Tightly regulated long-term erythropoietin expression in vivo using tet-inducible recombinant adeno-associated viral vectors. Hum. Gene Ther. 13: 335-342.
35. Lamartina, S., et al. (2002). Stringent control of gene expression in vivo by using novel doxycycline-dependent trans-activators. Hum. Gene Ther. 13: 199-210.
36. Baron, U., and Bujard, H. (2000). Tet repressor-based system for regulated gene expression in eukaryotic cells: Principles and advances. Methods Enzymol. 327: 401-421.
37. Lamartina, S., et al. (2003). Construction of an rtTA2(s)-m2/tts(kid)-based transcription regulatory switch that displays no basal activity, good inducibility, and high responsiveness to doxycycline in mice and non-human primates. Mol. Ther. 7: 271-280.
38. Dong, J. Y., Fan, P. D., and Frizzell, R. A. (1996). Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum. Gene Ther. 7: 2101-2112.
39. Koponen, J. K., et al. (2003). Doxycycline-regulated lentiviral vector system with a novel reverse transactivator rtTA2(S)-M2 shows a tight control of gene expression in vitro and in vivo. Gene Ther. 10: 459-466.
40. Chao, H., et al. (2000). Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol. Ther. 2: 619-623.